The FDA has approved Orbactiv (oritavancin), from The Medicines Company, for injection for the treatment of adults with Acute Bacterial...
The European Commission has granted marketing authorization for Orbactiv (oritavancin), from The Medicines Co, for acute bacterial skin and skin...
Melinta Therapeutics announced that findings from the first phase of the ongoing Clinical and Historic Registry and Orbactiv Medical Evaluation...
The Medicines Company announced that it has entered into a definitive agreement to sell its infectious disease business unit to...
The Medicines Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Melinta Therapeutics, LLC announced that the FDA has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
The FDA has approved Kimyrsa (oritavancin), from Melinta Therapeutics, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Tenkasi (oritavancin) from Menarini International Operations Luxembourg S.A.
Melinta Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...